GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » Capital Expenditure

Nanobiotix (XPAR:NANO) Capital Expenditure : €-0.50 Mil (TTM As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Nanobiotix Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Nanobiotix's cash flow for capital expenditures for the six months ended in Jun. 2024 was €-0.49 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.50 Mil.

Nanobiotix Capital Expenditure Historical Data

The historical data trend for Nanobiotix's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanobiotix Capital Expenditure Chart

Nanobiotix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -0.11 -0.23 -0.09 -0.34

Nanobiotix Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.01 -0.32 -0.01 -0.49

Nanobiotix Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » Capital Expenditure
Comparable Companies
XPAR:ALCLS XPAR:OSE XPAR:IPH XPAR:GNFT XPAR:IVA XPAR:MAAT XPAR:ALSEN XPAR:TNG XPAR:ADOC XPAR:DBV VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
NBTX:USA 0QAV:UK 5NRA:Germany
Address
60 Rue de Wattignies, Paris, FRA, 75012
Website
https://www.nanobiotix.com
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix Headlines

No Headlines